New Amgen drug still under review
- Share via
From Times Staff and Wires
Biotechnology company Amgen Inc. said U.S. regulators would take additional time to review Nplate, a new drug for a bleeding disorder that affects 60,000 Americans.
The Food and Drug Administration had been expected to decide whether to approve the drug by Wednesday, Amgen said. The Thousand Oaks company didn’t say why regulators postponed the decision or when it might come.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
